May 14, 2020 – Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).“The orphan drug designation is an important regulatory milestone as we further […]
-
Recent Posts
- Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome
- Cellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based Hemostatic
- Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients
- Cellphire Awarded $29.25 Million U.S. Army Cryopreserved Platelet Development Contract
- Transfusion News – Thrombosomes (Lyophilized Platelets) Appear Safe in Phase 1 Trial
-
Categories
- No categories
-
Archives